LB0012 HEADLINE RESULTS FOR A PHASE 4, 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS ADVERSE EVENTS OF SPECIAL INTEREST (AESI) IN ADULTS WITH ACTIVE, AUTOANTIBODY-POSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) RECEIVING BELIMUMAB

Saira SheikhMorton ScheinbergJames Cheng-Chung WeiDana TegzovaWilliam StohlTamara MucenicRoger LevyDamon BassJorge Ross TerrésRajesh PunwaneyJulia HarrisKevin ThorneloeBeulah JiDavid Roth2026-01-292026-01-292019-0610.1136/annrheumdis-2019-eular.8720https://scholars.csmu.edu.tw/handle/123456789/3833LB0012 HEADLINE RESULTS FOR A PHASE 4, 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS ADVERSE EVENTS OF SPECIAL INTEREST (AESI) IN ADULTS WITH ACTIVE, AUTOANTIBODY-POSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) RECEIVING BELIMUMABjournal-article